<?xml version="1.0" encoding="UTF-8"?>
<ref id="pone.0223487.ref041">
 <label>41</label>
 <mixed-citation publication-type="journal">
  <name>
   <surname>Baeten</surname>
   <given-names>JM</given-names>
  </name>, 
  <name>
   <surname>Heffron</surname>
   <given-names>R</given-names>
  </name>, 
  <name>
   <surname>Kidoguchi</surname>
   <given-names>L</given-names>
  </name>, 
  <name>
   <surname>Mugo</surname>
   <given-names>NR</given-names>
  </name>, 
  <name>
   <surname>Katabira</surname>
   <given-names>E</given-names>
  </name>, 
  <name>
   <surname>Bukusi</surname>
   <given-names>EA</given-names>
  </name>, 
  <etal>et al</etal>
  <article-title>Integrated Delivery of Antiretroviral Treatment and Pre-exposure Prophylaxis to HIV-1-Serodiscordant Couples: A Prospective Implementation Study in Kenya and Uganda</article-title>. 
  <source>PLoS Med</source>. 
  <year>2016</year>;
  <volume>13</volume>(
  <issue>8</issue>):
  <fpage>e1002099</fpage> Epub 2016/08/24. 
  <pub-id pub-id-type="doi">10.1371/journal.pmed.1002099</pub-id> interests: Gilead Sciences donated the PrEP medication used in this study. CH received prior funding (05/01/09-04/30/10) for a pharmacokinetics study of TDF in the colon and female genital tract from Gilead Sciences and has a patent pending using a different formulation of the drug used in this study.
  <?supplied-pmid 27552090?>
  <pub-id pub-id-type="pmid">27552090</pub-id>
 </mixed-citation>
</ref>
